News – Page 8 – Myeloma Academy

Jul302019

NICE to consider lenalidomide maintenance treatment for myeloma patients post high dose therapy and stem cell transplantation

Lenalidomide (Revlimid®) maintenance for myeloma patients who have undergone high dose therapy and stem cell transplantation (HDT-SCT) will be considered for use on the NHS by The National Institute for Health and Care Excellence (NICE) later this year. This announcement comes after updated advice from the manufacturer Celgene and follows publication of data from the Myeloma XI clinical…

Details

July 30, 2019NewsBy amycapper

Jul102019

Daratumumab combinations are effective for the treatment of newly diagnosed myeloma.

Results from two phase III clinical trials (MAIA and CASSOPIEA) evaluating daratumumab (Darzalex®) combinations for the treatment of newly diagnosed myeloma patients have been recently published. The data provide evidence to support the use of daratumumab for the treatment of newly diagnosed myeloma patients whether they are eligible for high dose therapy and stem cell…

Details

July 10, 2019News, UncategorizedBy carolined

Jul82019

Daratumumab combination treatment approved for use on the NHS in Scotland

Myeloma patients at first relapse in Scotland will now be able to access the new treatment of daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone on the NHS after it was approved for use by the Scottish Medicines Consortium (SMC). This decision brings Scotland into line with the rest of the UK following the decision by NICE…

Details

July 8, 2019NewsBy amycapper

Jun252019

Myeloma UK and the UK Myeloma Research Alliance launch new research programme

Myeloma UK is launching a new research programme to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme (UKMRA-Myeloma UK-CARP). This initiative is part of an ambitious new strategy Myeloma UK recently published with a mission to make myeloma history. One of our key…

Details

June 25, 2019NewsBy amycapper

Double approval from NICE increases NHS treatment options in England and Wales

The National Institute of Health and Care Excellence (NICE) has approved the myeloma treatment lenalidomide (Revlimid®) and dexamethasone for use in treating newly diagnosed patients and patients at first relapse. The decision means that lenalidomide and dexamethasone will now be available on the NHS to patients in England and Wales who are not eligible for…

Details

May 20, 2019NewsBy amycapper

Apr252019

Myeloma Grand Rounds: a training mechanism to speed up diagnosis in secondary care

Myeloma is a relapsing-remitting blood cancer arising from the clonal expansion of abnormal plasma cells in the bone marrow. It is a difficult cancer to diagnose due to the vagueness of symptoms and rarity of the disease. This means myeloma patients experience some of the longest delays in diagnosis of all cancer patients. Myeloma UK…

Details

April 25, 2019NewsBy hparkin

Daratumumab combination treatment approved for NHS use in England and Wales through the Cancer Drugs Fund

This new treatment combination is being made available via the CDF on the NHS for the first time following a recommendation by the National Institute of Health and Care Excellence (NICE). This decision follows an earlier draft negative decision by NICE in July last year. Daratumumab, which is produced by the pharmaceutical company Janssen, belongs to a…

Details

April 18, 2019NewsBy hparkin

Feb132019

Collaborative research and supporter funding key to finding a cure for myeloma

Finding answers to discover a cure for myeloma is one of our main objectives at Myeloma UK. We are committed to achieving this with the help of supporters such as Alison Goldberg and Sara Phillips, who are trustees of The Joyce and Norman Freed Charitable Trust, which they established in 2016 to help fund projects…

Details

February 13, 2019NewsBy amycapper

Myeloma UK publishes report on Patient Reported Outcome Measures (PROMs) in Myeloma

This month Myeloma UK published a new research report recommending that researchers, the NHS and healthcare professionals work together to improve the way that patient reported outcome measures (PROMs) are utilised in myeloma research. PROMs are questionnaires that are completed by patients and are often used either in a clinical trial setting to measure the impact of a…

Details

August 30, 2018NewsBy amycapper

Phase III pomalidomide trial reaches primary endpoint

Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…

Details

February 8, 2018NewsBy sarahfleming